Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.

O'Connor OA, Özcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A, Caballero D, Horwitz SM, Lennard A, Turgut M, Hamerschlak N, d'Amore FA, Foss F, Kim WS, Leonard JP, Zinzani PL, Chiattone CS, Hsi ED, Trümper L, Liu H, Sheldon-Waniga E, Ullmann CD, Venkatakrishnan K, Leonard EJ, Shustov AR; Lumiere Study Investigators.

J Clin Oncol. 2019 Feb 1:JCO1800899. doi: 10.1200/JCO.18.00899. [Epub ahead of print]

PMID:
30707661
2.

Does end-of-treatment FDG-PET improve outcomes in follicular lymphoma? - Authors' reply.

Trotman J, Barrington SF, Meignan M; PET investigators from the GALLIUM study.

Lancet Oncol. 2019 Jan;20(1):e5. doi: 10.1016/S1470-2045(18)30933-1. No abstract available.

PMID:
30614478
3.

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.

Trotman J, Barrington SF, Belada D, Meignan M, MacEwan R, Owen C, Ptáčník V, Rosta A, Fingerle-Rowson GR, Zhu J, Nielsen T, Sahin D, Hiddemann W, Marcus RE, Davies A; PET investigators from the GALLIUM study.

Lancet Oncol. 2018 Nov;19(11):1530-1542. doi: 10.1016/S1470-2045(18)30618-1. Epub 2018 Oct 8.

PMID:
30309758
4.

A recap of RNA recapping.

Trotman JB, Schoenberg DR.

Wiley Interdiscip Rev RNA. 2019 Jan;10(1):e1504. doi: 10.1002/wrna.1504. Epub 2018 Sep 5. Review.

PMID:
30252202
5.

Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma.

Trotman J, Cheah CY, Marlton P, Opat S.

Intern Med J. 2018 Sep 19. doi: 10.1111/imj.14113. [Epub ahead of print] Review.

PMID:
30230156
6.

RNA-binding proteins and heat-shock protein 90 are constituents of the cytoplasmic capping enzyme interactome.

Trotman JB, Agana BA, Giltmier AJ, Wysocki VH, Schoenberg DR.

J Biol Chem. 2018 Oct 26;293(43):16596-16607. doi: 10.1074/jbc.RA118.004973. Epub 2018 Aug 30.

PMID:
30166341
7.

Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.

Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE.

J Clin Oncol. 2018 Aug 10;36(23):2395-2404. doi: 10.1200/JCO.2017.76.8960. Epub 2018 Jun 1.

PMID:
29856692
8.

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.

Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia.

N Engl J Med. 2018 Jun 21;378(25):2399-2410. doi: 10.1056/NEJMoa1802917. Epub 2018 Jun 1.

9.

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.

Gopal AK, Schuster SJ, Fowler NH, Trotman J, Hess G, Hou JZ, Yacoub A, Lill M, Martin P, Vitolo U, Spencer A, Radford J, Jurczak W, Morton J, Caballero D, Deshpande S, Gartenberg GJ, Wang SS, Damle RN, Schaffer M, Balasubramanian S, Vermeulen J, Cheson BD, Salles G.

J Clin Oncol. 2018 Aug 10;36(23):2405-2412. doi: 10.1200/JCO.2017.76.8853. Epub 2018 May 31.

PMID:
29851546
10.

RNA Cap Methyltransferase Activity Assay.

Trotman JB, Schoenberg DR.

Bio Protoc. 2018 Mar 20;8(6). pii: e2767. doi: 10.21769/BioProtoc.2767.

11.

Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study.

Cottereau AS, Versari A, Luminari S, Dupuis J, Chartier L, Casasnovas RO, Berriolo-Riedinger A, Menga M, Haioun C, Tilly H, Tarantino V, Federico M, Salles G, Trotman J, Meignan M.

Blood. 2018 May 31;131(22):2449-2453. doi: 10.1182/blood-2017-11-816298. Epub 2018 Mar 20.

PMID:
29559480
12.

Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenström macroglobulinemia.

Othman J, Verner E, Tam CS, Huang J, Lin L, Hilger J, Trotman J, Gasiorowski R.

Haematologica. 2018 May;103(5):e223-e225. doi: 10.3324/haematol.2017.186817. Epub 2018 Feb 8. No abstract available.

13.

RNA guanine-7 methyltransferase catalyzes the methylation of cytoplasmically recapped RNAs.

Trotman JB, Giltmier AJ, Mukherjee C, Schoenberg DR.

Nucleic Acids Res. 2017 Oct 13;45(18):10726-10739. doi: 10.1093/nar/gkx801.

14.

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.

Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group.

Lancet. 2017 Aug 5;390(10094):555-566. doi: 10.1016/S0140-6736(17)31266-7. Epub 2017 Jun 7.

PMID:
28600132
15.

Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.

Thieblemont C, Tilly H, Gomes da Silva M, Casasnovas RO, Fruchart C, Morschhauser F, Haioun C, Lazarovici J, Grosicka A, Perrot A, Trotman J, Sebban C, Caballero D, Greil R, van Eygen K, Cohen AM, Gonzalez H, Bouabdallah R, Oberic L, Corront B, Choufi B, Lopez-Guillermo A, Catalano J, Van Hoof A, Briere J, Cabeçadas J, Salles G, Gaulard P, Bosly A, Coiffier B.

J Clin Oncol. 2017 Aug 1;35(22):2473-2481. doi: 10.1200/JCO.2017.72.6984. Epub 2017 Apr 20.

PMID:
28426350
16.

Report of the 6th International Workshop on PET in lymphoma.

Nanni C, Cottereau AS, Lopci E, Bodet-Milin C, Coronado M, Pro B, Kim WS, Trotman J, Barrington S, Duhrsen U, Vander Borght T, Zamagni E, Kraeber-Bodéré F, Messiou C, Rahmouni A, Buvat I, Andre M, Hertzberg M, Oyen W, Casasnovas O, Luminari S, Garderet L, Montravers F, Kobe C, Kluge R, Versari A, Zucca E, Moreau P, Cheson B, Haioun C, Gallamini A, Meignan M.

Leuk Lymphoma. 2017 Oct;58(10):2298-2303. doi: 10.1080/10428194.2017.1298752. Epub 2017 Mar 7.

PMID:
28264597
17.

Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.

Quach H, Fernyhough L, Henderson R, Corbett G, Baker B, Browett P, Blacklock H, Forsyth C, Underhill C, Cannell P, Trotman J, Neylon A, Harrison S, Link E, Swern A, Cowan L, Dimopoulos MA, Miles Prince H.

Br J Haematol. 2017 May;177(3):441-448. doi: 10.1111/bjh.14562. Epub 2017 Feb 15.

PMID:
28197996
18.

Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.

Hertzberg M, Gandhi MK, Trotman J, Butcher B, Taper J, Johnston A, Gill D, Ho SJ, Cull G, Fay K, Chong G, Grigg A, Lewis ID, Milliken S, Renwick W, Hahn U, Filshie R, Kannourakis G, Watson AM, Warburton P, Wirth A, Seymour JF, Hofman MS, Hicks RJ; Australasian Leukaemia Lymphoma Group (ALLG).

Haematologica. 2017 Feb;102(2):356-363. doi: 10.3324/haematol.2016.154039. Epub 2016 Nov 10.

19.

Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

Talaulikar D, Tam CS, Joshua D, Ho JP, Szer J, Quach H, Spencer A, Harrison S, Mollee P, Roberts AW, Horvath N, Lee C, Zannettino A, Brown R, Augustson B, Jaksic W, Gibson J, Kalff A, Johnston A, Trotman J, Kalro A, Grigoriadis G, Ward C, Prince HM.

Intern Med J. 2017 Jan;47(1):35-49. doi: 10.1111/imj.13311.

PMID:
28076910
20.

Reply to H.J.A. Adams et al and E. Laffon et al.

Meignan M, Cottereau AS, Versari A, Chartier L, Dupuis J, Boussetta S, Grassi I, Casasnovas RO, Haioun C, Tilly H, Tarantino V, Dubreuil J, Federico M, Salles G, Luminari S, Trotman J.

J Clin Oncol. 2017 Mar 10;35(8):920-923. doi: 10.1200/JCO.2016.71.0459. Epub 2016 Dec 28. No abstract available.

PMID:
28029310
21.

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, García-Sanz R, Cornell RF, de Larrea CF, Castillo JJ, Granell M, Kyrtsonis MC, Leblond V, Symeonidis A, Kastritis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia.

Lancet Oncol. 2017 Feb;18(2):241-250. doi: 10.1016/S1470-2045(16)30632-5. Epub 2016 Dec 10.

PMID:
27956157
22.

Time to publish: challenging the performance of cooperative group lymphoma trials.

Federico M, Trotman J, Dreyling M.

Lancet Haematol. 2017 Jan;4(1):e8-e10. doi: 10.1016/S2352-3026(16)30084-9. Epub 2016 Dec 2. No abstract available.

PMID:
27916630
23.

Formalising multidisciplinary peer review: developing a haematological malignancy-specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence-based clinical practice.

Trotman J, Trinh J, Kwan YL, Estell JA, Fletcher J, Archer K, Lee K, Foo K, Curnow J, Bianchi A, Wignall L, Verner E, Gasiorowski R, Siedlecka E, Cunningham I.

Intern Med J. 2017 May;47(5):542-548. doi: 10.1111/imj.13302.

PMID:
27753208
24.

Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

Johnson P, Trotman J, Federico M.

N Engl J Med. 2016 Sep 8;375(10):999-1000. doi: 10.1056/NEJMc1609333. No abstract available.

PMID:
27602676
25.

Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies.

Meignan M, Cottereau AS, Versari A, Chartier L, Dupuis J, Boussetta S, Grassi I, Casasnovas RO, Haioun C, Tilly H, Tarantino V, Dubreuil J, Federico M, Salles G, Luminari S, Trotman J.

J Clin Oncol. 2016 Oct 20;34(30):3618-3626. doi: 10.1200/JCO.2016.66.9440. Epub 2016 Sep 30.

PMID:
27551111
26.

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, d'Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, O'Doherty M, Patrick P, Roberts T, Sidra G, Stevens L, Smith P, Trotman J, Viney Z, Radford J, Barrington S.

N Engl J Med. 2016 Jun 23;374(25):2419-29. doi: 10.1056/NEJMoa1510093.

27.

High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation.

Nath CE, Trotman J, Tiley C, Presgrave P, Joshua D, Kerridge I, Kwan YL, Gurney H, McLachlan AJ, Earl JW, Nivison-Smith I, Zeng L, Shaw PJ.

Br J Clin Pharmacol. 2016 Jul;82(1):149-59. doi: 10.1111/bcp.12906. Epub 2016 Apr 27.

28.

PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study.

Barrington SF, Kirkwood AA, Franceschetto A, Fulham MJ, Roberts TH, Almquist H, Brun E, Hjorthaug K, Viney ZN, Pike LC, Federico M, Luminari S, Radford J, Trotman J, Fosså A, Berkahn L, Molin D, D'Amore F, Sinclair DA, Smith P, O'Doherty MJ, Stevens L, Johnson PW.

Blood. 2016 Mar 24;127(12):1531-8. doi: 10.1182/blood-2015-11-679407. Epub 2016 Jan 8.

29.

Deliverability and efficacy of R-CHOP chemotherapy in very elderly patients with diffuse large B-cell lymphoma: an Australian retrospective analysis.

Millar A, Ellis M, Mollee P, Cochrane T, Fletcher J, Caudron A, Webster B, Trotman J.

Intern Med J. 2015 Nov;45(11):1147-53. doi: 10.1111/imj.12889.

PMID:
26337606
30.

Reply to G. Keramida et al.

Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller S, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cheson BD.

J Clin Oncol. 2015 Dec 1;33(34):4121-2. doi: 10.1200/JCO.2015.63.2125. Epub 2015 Aug 24. No abstract available.

PMID:
26304890
31.

Epstein Barr virus-positive mucocutaneous ulcer of the colon associated Hodgkin lymphoma in Crohn's disease.

Moran NR, Webster B, Lee KM, Trotman J, Kwan YL, Napoli J, Leong RW.

World J Gastroenterol. 2015 May 21;21(19):6072-6. doi: 10.3748/wjg.v21.i19.6072.

32.

Malignant peripheral nerve sheath tumor in cowden syndrome: a first report.

Taylor A, Delon I, Allinson K, Trotman J, Liu H, Abbs S, Tischkowitz M.

J Neuropathol Exp Neurol. 2015 Apr;74(4):288-92. doi: 10.1097/NEN.0000000000000178.

PMID:
25756585
33.

Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al.

Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller S, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cavalli F, Lister TA, Cheson BD.

J Clin Oncol. 2015 Apr 1;33(10):1221-3. doi: 10.1200/JCO.2014.59.9373. Epub 2015 Feb 17. No abstract available.

PMID:
25691678
34.

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.

Yeung DT, Osborn MP, White DL, Branford S, Braley J, Herschtal A, Kornhauser M, Issa S, Hiwase DK, Hertzberg M, Schwarer AP, Filshie R, Arthur CK, Kwan YL, Trotman J, Forsyth CJ, Taper J, Ross DM, Beresford J, Tam C, Mills AK, Grigg AP, Hughes TP; Australasian Leukaemia and Lymphoma Group.

Blood. 2015 Feb 5;125(6):915-23. doi: 10.1182/blood-2014-07-590315. Epub 2014 Dec 17.

35.

Positron emission tomography-computed tomography in follicular lymphoma: "one fit for all"?

Luminari S, Trotman J.

Leuk Lymphoma. 2015 May;56(5):1191-2. doi: 10.3109/10428194.2014.986482. Epub 2015 Jan 21. No abstract available.

PMID:
25407656
36.

Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies.

Trotman J, Luminari S, Boussetta S, Versari A, Dupuis J, Tychyj C, Marcheselli L, Berriolo-Riedinger A, Franceschetto A, Julian A, Ricard F, Guerra L, Haioun C, Biasoli I, Tilly H, Federico M, Salles G, Meignan M.

Lancet Haematol. 2014 Oct;1(1):e17-27. doi: 10.1016/S2352-3026(14)70008-0. Epub 2014 Sep 17. Erratum in: Lancet Haematol. 2014 Oct;1(1):e16.

PMID:
27030064
37.

Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cheson BD.

J Clin Oncol. 2014 Sep 20;32(27):3048-58. Erratum in: J Clin Oncol. 2016 Jul 20;34(21):2562.

38.

Rising cost of anticancer drugs in Australia.

Karikios DJ, Schofield D, Salkeld G, Mann KP, Trotman J, Stockler MR.

Intern Med J. 2014 May;44(5):458-63. doi: 10.1111/imj.12399.

PMID:
24612257
39.

PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study.

Tychyj-Pinel C, Ricard F, Fulham M, Fournier M, Meignan M, Lamy T, Vera P, Salles G, Trotman J.

Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):408-15. doi: 10.1007/s00259-013-2441-8. Epub 2014 Jan 17.

PMID:
24435770
40.

Evaluating the place of 18-fluoro-2-deoxy-D-glucose positron emission tomography scanning in primary staging and beyond in patients with follicular lymphoma.

Seymour JF, Trotman J, Hofman MS.

Leuk Lymphoma. 2013 Oct;54(10):2093-5. doi: 10.3109/10428194.2013.800201. No abstract available.

PMID:
23641872
41.

Rapidly fatal post-allogeneic stem cell transplant lymphoproliferative disorder presenting with skin and bone marrow involvement.

Gasiorowski R, Gibson J, Watson G, Trotman J, Larsen S.

Pathology. 2013 Jan;45(1):81-3. doi: 10.1097/PAT.0b013e32835b5de4. No abstract available.

PMID:
23255032
42.

Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experience.

Kiely BE, McCaughan G, Christodoulou S, Beale PJ, Grimison P, Trotman J, Tattersall MH, Stockler MR.

Support Care Cancer. 2013 Feb;21(2):369-76. doi: 10.1007/s00520-012-1526-4. Epub 2012 Jun 21.

PMID:
22717918
43.

Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.

Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A, Shpilberg O, Gyan E, Tilly H, Estell J, Forsyth C, Decaudin D, Fabiani B, Gabarre J, Salles B, Van Den Neste E, Canioni D, Garin E, Fulham M, Vander Borght T, Salles G.

J Clin Oncol. 2011 Aug 10;29(23):3194-200. doi: 10.1200/JCO.2011.35.0736. Epub 2011 Jul 11.

PMID:
21747087
44.

Role of early PET in the management of diffuse large B-cell lymphoma.

Michallet AS, Trotman J, Tychyj-Pinel C.

Curr Opin Oncol. 2010 Sep;22(5):414-8. doi: 10.1097/CCO.0b013e32833d5905. Review.

PMID:
20683268
45.

Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy.

Nath CE, Shaw PJ, Trotman J, Zeng L, Duffull SB, Hegarty G, McLachlan AJ, Gurney H, Kerridge I, Kwan YL, Presgrave P, Tiley C, Joshua D, Earl J.

Br J Clin Pharmacol. 2010 May;69(5):484-97. doi: 10.1111/j.1365-2125.2010.03638.x.

46.

Consensus guidelines for 'rainy day' autologous stem cell harvests in New South Wales.

Trotman J, Presgrave P, Kwan Y, Tiley C, Estell J, Watson AM, O'Brien TA, Peters D.

Intern Med J. 2008 Apr;38(4):229-34. doi: 10.1111/j.1445-5994.2008.01632.x.

PMID:
18380700
47.

Subacute cardiac toxicity following autologous haematopoietic stem cell transplantation in patients with normal cardiac function.

Chung T, Lim WC, Sy R, Cunningham I, Trotman J, Kritharides L.

Heart. 2008 Jul;94(7):911-8. Epub 2007 Dec 10.

PMID:
18070952
48.

Pharmacokinetics of melphalan in myeloma patients undergoing an autograft.

Nath CE, Shaw PJ, Trotman J, Zeng L.

Bone Marrow Transplant. 2007 Oct;40(7):707-8. Epub 2007 Aug 6. No abstract available.

PMID:
17680022
49.

Haemorrhagic cystitis: incidence and risk factors in a transplant population using hyperhydration.

Trotman J, Nivison-Smith I, Dodds A.

Bone Marrow Transplant. 1999 Apr;23(8):797-801.

50.

Paradigm for SCI nurse competency on adult-geriatric SCI rehabilitation unit.

Thomason SS, Binard JE, Gregg B, Padios E, Trotman J.

SCI Nurs. 1996 Dec;13(4):101-4. Review.

PMID:
9165948

Supplemental Content

Loading ...
Support Center